Anti-inflammatory effect of galectin-1 in a murine model of atopic dermatitis

Anti-inflammatory effect of galectin-1 in a murine model of atopic dermatitis Atopic dermatitis (AD) is caused by both dysregulated immune Key messages & Pharmacological treatment with rGal-1 reduces clinical responses and an impaired skin barrier. Although beta- galactoside-binding protein galectin-1 (Gal-1) has immuno- signs of atopic dermatitis. & Systemic treatment with rGal-1 inhibits eosinophil and modulatory effects in several inflammatory disorders, therapeu- mast cell influx in the skin of AD animals. tic strategies based on its anti-inflammatory properties have not been explored in AD. Thus, we evaluate pharmacological treat- & rGal-1 reduced local eotaxin levels and systemic IL-17 levels. ment with Gal-1 in the progression of an ovalbumin (OVA)- induced AD-like skin lesions. The skin of OVA-immunized & The inhibition of disease progression induced by rGal-1 was correlated with upregulation of phosphorylated ERK. male BALB/c mice was challenged with drops containing OVA on days 11, 14–18 and 21–24. Additionally, in the last . . . week, a subset of animals was treated intraperitoneally with Keywords Galectin-1 Skin inflammation Ovalbumin . . recombinant Gal-1 (rGal-1) or dexamethasone (Dex). Eosinophil Mast cell ERK Treatment with rGal-1 decreased the clinical signs of dermatitis in BALB/c mice and diminished local eotaxin and IFN-γ levels. The treatment also suppressed the infiltration of eosin- Introduction ophils http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Molecular Medicine Springer Journals

Anti-inflammatory effect of galectin-1 in a murine model of atopic dermatitis

Loading next page...
 
/lp/springer_journal/anti-inflammatory-effect-of-galectin-1-in-a-murine-model-of-atopic-r7LxOqnMbA
Publisher
Springer Berlin Heidelberg
Copyright
Copyright © 2017 by Springer-Verlag GmbH Germany
Subject
Biomedicine; Molecular Medicine; Human Genetics; Internal Medicine
ISSN
0946-2716
eISSN
1432-1440
D.O.I.
10.1007/s00109-017-1566-9
Publisher site
See Article on Publisher Site

Abstract

Atopic dermatitis (AD) is caused by both dysregulated immune Key messages & Pharmacological treatment with rGal-1 reduces clinical responses and an impaired skin barrier. Although beta- galactoside-binding protein galectin-1 (Gal-1) has immuno- signs of atopic dermatitis. & Systemic treatment with rGal-1 inhibits eosinophil and modulatory effects in several inflammatory disorders, therapeu- mast cell influx in the skin of AD animals. tic strategies based on its anti-inflammatory properties have not been explored in AD. Thus, we evaluate pharmacological treat- & rGal-1 reduced local eotaxin levels and systemic IL-17 levels. ment with Gal-1 in the progression of an ovalbumin (OVA)- induced AD-like skin lesions. The skin of OVA-immunized & The inhibition of disease progression induced by rGal-1 was correlated with upregulation of phosphorylated ERK. male BALB/c mice was challenged with drops containing OVA on days 11, 14–18 and 21–24. Additionally, in the last . . . week, a subset of animals was treated intraperitoneally with Keywords Galectin-1 Skin inflammation Ovalbumin . . recombinant Gal-1 (rGal-1) or dexamethasone (Dex). Eosinophil Mast cell ERK Treatment with rGal-1 decreased the clinical signs of dermatitis in BALB/c mice and diminished local eotaxin and IFN-γ levels. The treatment also suppressed the infiltration of eosin- Introduction ophils

Journal

Journal of Molecular MedicineSpringer Journals

Published: Jun 29, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off